25 results about "Sustained release drug" patented technology

The invention relates to the technical field of drug sustained release, and discloses a wearable multi-drug sustained release device which comprises a flexible base material, a sustained release drug delivery structure comprises a microneedle array cluster distributed on the inner side of the flexible base material, a modular drug box is arranged on one side of the microneedle array cluster, and a controlled release module is arranged on the inner side of the flexible base material; a snap fastener is fixed on the surface of the friction belt, and a rope binding belt is sewn on the flexible base material. According to the wearable multi-drug sustained release device, when the flexible base material and the flexible cavity tube deform, stress is mainly absorbed and extended by the flexible cavity tube, the rigid convex block bearing the microneedle cluster tube is kept stable, the angle is automatically adjusted to keep vertical puncture force on the skin surface, and the stability of the microneedle puncture state is ensured; different medicine storage boxes have different RFID identifications, and the effect of administration of different medicines at the same affected part can be achieved; for different sizes of binding parts, the binding stability can be improved by adopting snap fasteners or rope binding belts.

The present invention relates to a bio-orthogonal, biodegradable hydrogel for sustained drug delivery, a method for preparing a bio-orthogonal, biodegradable hydrogel, the use thereof as an implantable material in the treatment of disease, and a method for preparing the same. As well as kits for preparing the hydrogels in situ at a treatment site and methods of treatment using the hydrogels or kits, such as for the treatment of ocular diseases.

The invention relates to the technical field of nano microspheres, in particular to a preparation method and application of salicylic acid nano microspheres. Through the synergistic effect of a series of key technical links such as raw material selection, step-by-step crosslinking, particle size control and fine purification, the salicylic acid nano microspheres are prepared; salicylic acid is prepared into nano microspheres with low irritation, high stability, good solubility, high drug loading capacity, high encapsulation efficiency and controllable drug release behavior, controlled release and slow release of drugs are achieved, the problem that traditional salicylic acid is uneven in in-vitro release rate is solved, the controlled release characteristic compared with an original drug is shown after encapsulation, and the drug release behavior is controllable. Especially in an acidic environment, the microspheres can delay and continuously release drugs, and have intelligent responsiveness. The salicylic acid derivative-based nano-microspheres can simultaneously deliver various drugs or bioactive substances, so that synergistic treatment is realized, and the salicylic acid derivative-based nano-microspheres can be widely applied to the fields of cosmetics and medicines.

Bioadhesive and biodegradable polymeric nanoparticles can be administered intrathecally, for example, via the cisterna magna, into the spinal column to allow widespread distribution for the treatment of tumors such as leptomeningeal metastases. The nanoparticles rapidly spread to all cerebrospinal fluid (CSF) compartments, including the brain parenchyma and spinal column. The bioadhesive nanoparticles penetrate and are retained for long periods of time, during which time they can continue to release drugs. These nanoparticles can be loaded with different therapeutic, preventive, or diagnostic agents, most preferably DNA repair inhibitors, to enhance the killing of leptomeningeal tumors, such as leptomeningeal metastases, and disseminated tumors, such as medulloblastoma. In a preferred embodiment, patients are treated with a combination of a PARP inhibitor and temozolomide.

The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng / mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.

The invention relates to biological adhesive powder for preventing stenosis after endoscopic mucosal dissection of esophageal premature cancer. The biological adhesive powder comprises a silk fibroin-polyphenol cross-linked network and an adhesive layer, wherein the silk fibroin-polyphenol cross-linked network is formed by cross-linking a silk fibroin solution and a polyphenol solution through phenolic hydroxyl groups; the mass ratio of the glucocorticoid carried in the cross-linked network to the adhesive powder is (1: 40)-(1: 50); the structural characteristic is that the content of beta-sheet conformation in Fourier infrared spectroscopy is greater than or equal to 20%. The preparation method comprises the following steps: mixing the silk fibroin-polyphenol basic powder with the therapeutic drug, activating the mixture into gel by using a 20-50% ethanol aqueous solution, and then performing secondary freeze drying. In a miniature pig esophageal ESD operation model, after being sprayed to a wound surface and activated into hydrogel, the powder can be stably attached to the wound surface for more than 14 days, is gradually degraded and releases glucocorticoid, and can continuously release more than or equal to 80% of medicine within 72 hours, so that esophageal stenosis is effectively inhibited.

A method for designing and manufacturing a long release capsule for extended delivery of a drug to a patient in an ingestible capsule. The method includes determining a drug volume to be delivered and a drug delivery rate. A buoyancy element is selected based on the drug volume. A release port is selected based on the drug delivery rate and the properties of the drug. The design elements are used to produce a capsule design for an ingestible capsule. The design of the capsule is used to generate manufacturing instructions and produce the capsule.

The application provides a modified Zein Pickering emulsion, a preparation method thereof and application of the Pickering emulsion in fresh-keeping of sandgrass at room temperature, and belongs to the technical field of food fresh-keeping. The preparation method comprises the following steps: Zein is added into an alkaline solution for amino treatment, and after high-temperature reaction, the solution is cooled and the pH value of the solution is adjusted. After removing impurities, the solid sample is obtained through freeze-drying; the obtained sample is added into water together with another natural extract for reaction, the solution is transferred after a period of time, and impurities are removed, and then the modified Zein polymer coating is obtained through freeze-drying; the modified Zein material is added into water together with cinnamyl aldehyde, and after emulsification by using an ultrasonic homogenizer, the target Pickering emulsion is obtained. The Pickering emulsion obtained by the application has the advantages of sustained drug release, high external tolerance, anti-freeze-thaw cycle, excellent sterilization performance and outstanding antioxidant performance, and can be applied to fresh-keeping of sandgrass at room temperature.

The utility model relates to the technical field of medical instruments, in particular to a drug sustained-release cartilage support. The drug sustained-release cartilage stent comprises a plurality of support units which are overlapped in sequence, each supporting unit comprises two polygonal structures, and the two polygonal structures are connected in a three-dimensional mode through a plurality of parallel V-shaped connecting parts. And the polygonal structure is formed by connecting two groups of parallel V-shaped connecting parts end to end. The drug sustained-release cartilage stent can be compressed when being implanted, and rebounds after being implanted, so that mechanical support is realized. Meanwhile, triangular bulges or grooves are formed in the surface of the porous scaffold constructed by the V-shaped connecting parts, so that embedding with surrounding tissues is facilitated.

The present invention relates to a solid oral pharmaceutical for Tetrahydrocannabinol (API) or any other Cannabinoid (API) with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Tetrahydrocannabinol and other Cannabinoids can be found in a wide range of indications like pain relief, insomnia, anti- depression and others.

The invention belongs to the technical field of biological medicine, and particularly discloses a biomacromolecule slow-release metal-polyphenol compound as well as a preparation method and application thereof. The compound comprises metal ions, aromatic alkyl amine polyphenol and a biological macromolecular active drug, wherein the aromatic alkyl amine polyphenol is a compound with a structural general formula as shown in a formula (I), a formula (II), a formula (III) or a formula (IV) or a pharmaceutically acceptable salt of the compound. The compound is formed by self-assembly of metal ions, polyphenol and active drugs under a water phase condition, efficient entrapment of biological macromolecular drugs can be achieved under a mild condition, the drug loading capacity is 1%-95%, and the entrapment efficiency is 1%-100%. The compound can realize controllable release of the loaded biomacromolecular drug, and presents a long-term and continuous slow-release drug delivery effect, so that the stability and bioavailability of the drug in vivo are effectively improved, the drug delivery frequency and potential adverse reaction are reduced, and the compound has a good application prospect.

Sustained release drug-loaded microparticles, pharmaceutical compositions comprising them, methods of making them, and methods of treatment using them are described.

The present invention relates to sustained release formulations of Potassium chloride crystals having a mesh size ranging from about 60 to 100 mesh, combined with one or more pharmaceutically acceptable excipients, wherein the potassium chloride crystals are coated with a coating solution comprising cellulosic polymer in an amount up to 9% w / w based on the total weight of the granules and to processes for their preparation.

The present disclosure provides for methods of producing analgesia in a subject. In some cases, methods produce analgesia in a subject undergoing arthroscopic subacromial decompression surgery. The present disclosure also relates to improved sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises bupivacaine N-oxide at a level less than 1 wt %, based on weight of the composition. In some cases, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.

The utility model relates to the technical field of medical instruments, in particular to a novel sustained-release drug delivery indwelling device for treating bladder cancer, which comprises a drug delivery indwelling main body, a controller is arranged on the right side of the top of the drug delivery indwelling main body, a groove is arranged on the left side of the top of the drug delivery indwelling main body, and a drug pushing assembly is arranged in an inner cavity of the groove. And the medicine pushing assembly comprises a motor, the motor is fixedly connected with one end of an inner cavity of the groove, a screw rod is arranged at the output end of the motor, the surface of the screw rod is in threaded connection with a thread sleeve, and the surface of the thread sleeve is fixedly sleeved with a pushing plate. Medicine is firstly stored in the container, then the container is fixed to the medicine administration indwelling body through the fixing assembly, at the moment, the output end of the container is fixed to the medicine administration position of a patient, and when medicine needs to be sprayed at regular time, the motor is fixed to run through the controller, the motor drives the screw to rotate, and the screw drives the threaded sleeve to move; and the push plate is driven to move through the threaded sleeve.

The invention relates to a sustained release biodegradable drag delivery system such as an implant comprising a hydrogel and a hydrophobic prodrug dispersed within the hydrogel, wherein the hydrophobic prodrug is a hydrophobic ester or amide derivative of a hydrophilic drag so that the prodrug solubility is less than 100 μg / ml, methods of manufacture, a kit: and an injection device comprising it and methods of treatment using the sustained release drug delivery system. The prodrug hydrophobicity is optimized to control the rate of prodrug release from the hydrogel implant.

Sustained release pharmaceutical compositions comprising a therapeutically effective amount of pyridostigmine or a pharmaceutically acceptable salt thereof, a diluent, and a copolymer comprising polyvinyl acetate and polyvinylpyrrolidone, wherein the compositions are produced by hot-melt extrusion.

The invention relates to the technical field of polymer hydrogel, in particular to a heat-sensitive injectable hydrogel material based on natural polysaccharide Sacran and poloxamer 407 and application of the heat-sensitive injectable hydrogel material in wound treatment. The hydrogel is prepared by a physical blending method, wherein P407 endows the material with excellent thermosensitive gelling property and injectability. The Sacran chain penetrates through a P407 network through physical entanglement and hydrogen-bond interaction to form a stable semi-interpenetrating structure, so that the mechanical strength, the water absorption swelling capacity and the biocompatibility of the hydrogel are enhanced. Furthermore, two medicines of tannic acid and dipotassium glycyrrhizinate are synergistically loaded, so that multiple functions of resisting bacteria, resisting oxidation, resisting inflammation and the like are integrated, and wound healing can be effectively promoted. The hydrogel prepared by the invention not only shows excellent heat sensitivity, mechanical property and cytocompatibility, but also can continuously release drugs, so that the treatment effect is further improved. The preparation process of the hydrogel is simple, convenient, efficient, green and environment-friendly. Wide clinical application prospects are realized in the fields of wound dressings and tissue engineering.

The present invention relates to novel bi-layer oral film composition comprising Nicotine or its pharmaceutically acceptable salt thereof. The present invention relates to novel Nicotine bi-layer oral film composition comprising sustained release drug layer and backing layer. The present invention specifically relates to novel bi-layer oral film composition comprising Nicotine or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the bi-layer oral film provides sustained release of drug. The present invention more specifically relates to process for the preparation of Nicotine bi-layer oral film.

The present invention relates to a solid oral pharmaceutical for Axitinib, Ibrutinib and / or Palbociclib (API) or any other Kinase Inhibitor API with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Axitinib, Ibrutinib and / or Palbociclib and other Kinase Inhibitors can be found for treatment of malign tumor diseases and others.

Deslorelin, in a medicinal or a non-medicinal product, for its use in chemical castration of a non-human mammal within 1 month after administration, wherein upon administration, the Cmax of deslorelin, at around 1 to 2 hours after administration, exceeds 7000 pg / mL and a deslorelin concentration in the non-human mammal plasma is at least 10 pg / mL. Also, a sustained release drug delivery system for implementing this use. Further, a method for chemically castrating a non-human animal including the steps of (a) administering an effective amount of deslorelin so as to obtain a Cmax concentration between 4000 pg / mL and 40000 pg / ml of plasma of deslorelin or an equivalent amount of a pharmaceutically acceptable salt thereof within first 24 h after injection; and thereafter, (b) administering a maintenance dose so that mean concentration is above 10 pg / ml of plasma of deslorelin or an equivalent amount of a pharmaceutically acceptable salt thereof.

The invention relates to a three-in-one hemorrhoid-preventing self-dissolving drug delivery treatment patch capable of being used in broad-spectrum underpants, and belongs to the technical field of medical care. The patch comprises a detachable adhesion layer, a temperature-sensitive slow-release layer and a core medicine layer, the core medicine layer is formed by compounding nanocarbon, marine active substances (algal polysaccharides and chitin), dragon's blood, borneol, gallnut, coptis chinensis and the like, and the targeting property is enhanced through a nanotechnology; and the temperature-sensitive slow-release layer adopts a compound of poly (N-isopropylacrylamide) (PNIPAM) and chitosan, and continuously releases drugs under the triggering of body temperature. The patch can be adhered to the crotch of a pair of underpants like a sanitary towel, can be self-dissolved for administration after being in contact with a focus, and is effective for internal and external hemorrhoids and mixed hemorrhoids. Clinical data show that the total effective rate reaches 95.8%, and no skin irritation is caused. The product integrates traditional Chinese medicines, nanotechnology and intelligent materials, and solves the problems of uncontrollable drug release and poor adaptability of the existing hemorrhoid patch.

The invention relates to a pain-relieving nano pasting film with a multi-layer composite structure and a preparation process of the pain-relieving nano pasting film, and belongs to the technical field of pasting film preparation. The genipin, the gelatin and the glutamine transaminase are added in the preparation process, so that the state that the collagen is dissolved when encountering water is changed, and the film achieves a slow-release effect; in addition, non-steroidal anti-inflammatory drugs such as diclofenac sodium or ibuprofen arginine are added, and the analgesic effect of the finished product is increased through synergism of the analgesic effect, the antipyretic effect and the effect of inhibiting synthesis of prostaglandin at the inflammation part. The pain-relieving nano pasting film prepared by the invention is a multi-dimensional three-dimensional film woven by multiple processes, the first layer of film is film cloth formed by modifying collagen through system active components and then spinning, and the pain-relieving nano pasting film not only can quickly transdermally relieve pain, but also can continuously release medicines; the second layer of film is an imitated human body sebum film and can effectively lock medicinal components; the pain-relieving nano pasting film prepared by the preparation process is light, thin and comfortable, is fit and free of burden in use, and does not irritate skin.

The invention relates to the technical field of nano materials applied to biomedicine or cosmetics, in particular to supramolecular nano delivery hydrogel as well as a preparation method and application thereof. The supramolecular nano delivery hydrogel provided by the invention has good pH value stability, excellent biocompatibility and relatively high adaptability while controllably and continuously releasing drugs and adjusting mechanical properties to match surrounding tissues; the problem of toxicity caused by the fact that gel is prepared from polymers in the prior art is solved, modification is not needed, the preparation cost is saved, the drug effect can be assisted to be exerted, and the hydrogel can be applied to delivery of hydrophobic drugs or cosmetic functional raw materials inside and outside a human body. More importantly, the nano-micelle hydrogel system is stable, the pH value can be adjusted to a human skin application range, and the nano-micelle hydrogel can be stably stored for a long time. The preparation method of the supramolecular nano delivery hydrogel is simple, mild in condition, cheap and easily available in raw materials and suitable for large-scale industrial production.

An implant is disclosed for the sustained delivery of a drug. The implant comprises a core comprising at least one drug distributed uniformly in a polymer matrix of a first non-erodible polymer. The i